Basel, 22nd July 2020 – Roche have today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.
The PDS with ranibizumab is a permanent refillable eye implant, approximately the size of a grain of rice, which is designed to continuously release a customised formulation of ranibizumab into the eye over time. Ranibizumab is an anti-VEGF agent, meaning that it works to inhibit the uncontrolled growth of blood-vessels within the eye which leak and lead to vision loss. This PDS also helps to relieve the treatment burden on patients who require frequent treatment, often at monthly intervals to preserve vision.
In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care, and according to Carl Regillo, M.D., Chief of Retina Service at Wills Eye Hospital in Philadelphia and an Archway study investigator; “PDS could potentially reduce the number of treatments from as many as 12 per year to two per year for neovascular AMD patients, without sacrificing efficacy,”.
Read the full press release from Roche here:
